Imaging genomics and response to treatment with antipsychotics in schizophrenia
- PMID: 16490418
- PMCID: PMC3593360
- DOI: 10.1016/j.nurx.2005.12.001
Imaging genomics and response to treatment with antipsychotics in schizophrenia
Abstract
Recent important advancements in genomic research have opened the way to new strategies for public health management. One of these questions pertains to how individual genetic variation may be associated with individual variability in response to drug treatment. The field of pharmacogenetics may have a profound impact on treatment of complex psychiatric disorders like schizophrenia. However, pharmacogenetic studies in schizophrenia have produced conflicting results. The first studies examined potential associations between clinical response and drug receptor genes. Subsequent studies have tried to use more objective phenotypes still in association with drug receptor genes. More recently, other studies have sought the association between putative causative or modifier genes and intermediate phenotypes. Thus, conflicting results may be at least in part explained by variability and choice of the phenotype, by choice of candidate genes, or by the relatively little knowledge about the neurobiology of this disorder. We propose that choosing intermediate phenotypes that allow in vivo measurement of specific neuronal functions may be of great help in reducing several of the potential confounds intrinsic to clinical measurements. Functional neuroimaging is ideally suited to address several of these potential confounds, and it may represent a powerful strategy to investigate the relationship between behavior, brain function, genes, and individual variability in the response to treatment with antipsychotic drugs in schizophrenia. Preliminary evidence with potential susceptilibity genes such as COMT, DISC1, and GRM3 support these assumptions.
Similar articles
-
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.Mol Psychiatry. 2007 Aug;12(8):707-47. doi: 10.1038/sj.mp.4002009. Epub 2007 Jun 5. Mol Psychiatry. 2007. PMID: 17549063 Review.
-
Pharmacogenetics of antipsychoatics.Nagoya J Med Sci. 2004 May;67(1-2):1-7. Nagoya J Med Sci. 2004. PMID: 15279062 Review.
-
Model-based gene selection shows engrailed 1 is associated with antipsychotic response.Pharmacogenet Genomics. 2008 Sep;18(9):751-9. doi: 10.1097/FPC.0b013e32830162bc. Pharmacogenet Genomics. 2008. PMID: 18698228
-
Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes.Pharmacogenet Genomics. 2012 Nov;22(11):807-11. doi: 10.1097/FPC.0b013e3283586c04. Pharmacogenet Genomics. 2012. PMID: 23047292
-
Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia.Harv Rev Psychiatry. 2006 Mar-Apr;14(2):78-91. doi: 10.1080/10673220600642945. Harv Rev Psychiatry. 2006. PMID: 16603474 Review.
Cited by
-
Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics.Neuropsychopharmacology. 2015 Jun;40(7):1600-8. doi: 10.1038/npp.2015.5. Epub 2015 Jan 7. Neuropsychopharmacology. 2015. PMID: 25563748 Free PMC article.
-
[Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].Nervenarzt. 2006 Nov;77 Suppl 2:S65-74; quiz S75-6. doi: 10.1007/s00115-006-2197-5. Nervenarzt. 2006. PMID: 17072567 Review. German.
-
How antipsychotics work-from receptors to reality.NeuroRx. 2006 Jan;3(1):10-21. doi: 10.1016/j.nurx.2005.12.003. NeuroRx. 2006. PMID: 16490410 Free PMC article. Review.
-
Advances in the treatment of anxiety: targeting glutamate.NeuroRx. 2006 Jan;3(1):57-68. doi: 10.1016/j.nurx.2005.12.005. NeuroRx. 2006. PMID: 16490413 Free PMC article. Review.
-
Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.Psychiatry Res. 2009 Jul 15;173(1):31-8. doi: 10.1016/j.pscychresns.2008.09.001. Epub 2009 May 9. Psychiatry Res. 2009. PMID: 19428222 Free PMC article.
References
-
- McGuffin P, Riley B, Plomin R. Genomics and behavior. Toward behavioral genomics. Science. 2001;5507:1232–1249. - PubMed
-
- Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;1:40–68. - PubMed
-
- Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;4:405–411. - PubMed
-
- Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;7:660–669. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous